AR086476A2 - Metodos de produccion de una proteina de interes heterologa en una celula, para aumentar la productividad celular especifica de una proteina de interes de membrana o secretada en una celula, para aumentar la eficacia de transfeccion de una celula que expresa una proteina de interes de membrana o secretada en una celula y para identificar un modulador de la funcion de proteina con dominio start, vectores de expresion, celulas, proteinas, composiciones farmaceuticas y sus usos - Google Patents

Metodos de produccion de una proteina de interes heterologa en una celula, para aumentar la productividad celular especifica de una proteina de interes de membrana o secretada en una celula, para aumentar la eficacia de transfeccion de una celula que expresa una proteina de interes de membrana o secretada en una celula y para identificar un modulador de la funcion de proteina con dominio start, vectores de expresion, celulas, proteinas, composiciones farmaceuticas y sus usos

Info

Publication number
AR086476A2
AR086476A2 ARP120101384A ARP120101384A AR086476A2 AR 086476 A2 AR086476 A2 AR 086476A2 AR P120101384 A ARP120101384 A AR P120101384A AR P120101384 A ARP120101384 A AR P120101384A AR 086476 A2 AR086476 A2 AR 086476A2
Authority
AR
Argentina
Prior art keywords
protein
cell
interest
secreted
increase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ARP120101384A
Other languages
English (en)
Inventor
Hitto Kaufmann
Eric Becker
Monilola Olayioye
Angelika Hausser
Tim Fugmann
Lore Florin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07103406A external-priority patent/EP1964922A1/en
Application filed by Boehringer Ingelheim Pharma GmbH Co KG filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of AR086476A2 publication Critical patent/AR086476A2/es
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)

Abstract

Un método de producción de una proteína de interés heteróloga en una célula que comprende a) aumentar la expresión o actividad de una proteína que tiene una secuencia de amino ácidos que comprende un dominio de transferencia de lípido relacionado con la proteína reguladora de la esteroidogénesis aguda (START) o un derivado o mutante del mismo, en donde la proteína que tiene una secuencia de aminoácidos no comprende proteína de transferencia de ceramida (CERT), en donde el derivado no es una molécula de polipéptido al menos 70% idéntica en secuencia con la secuencia original CERT o su secuencia complementaria o dicho derivado no es una secuencia CERT homóloga de un organismo diferente y en donde dicho mutante no se basa en modificaciones dirigidas de secuencias CERT por sustitución, inserción o eliminación de uno a diez aminoácidos; y b) efectuar la expresión de dicha proteína de interés. Métodos para aumentar la productividad celular específica de una proteína de interés de membrana o secretada en una célula, para aumentar la eficacia de transfección de una célula que expresa una proteína de interés de membrana o secretada en una célula y para identificar un modulador de la función de proteína con dominio START, vectores de expresión, células, proteínas, composiciones farmacéuticas y sus usos.
ARP120101384A 2007-03-02 2012-04-20 Metodos de produccion de una proteina de interes heterologa en una celula, para aumentar la productividad celular especifica de una proteina de interes de membrana o secretada en una celula, para aumentar la eficacia de transfeccion de una celula que expresa una proteina de interes de membrana o secretada en una celula y para identificar un modulador de la funcion de proteina con dominio start, vectores de expresion, celulas, proteinas, composiciones farmaceuticas y sus usos Pending AR086476A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07103406A EP1964922A1 (en) 2007-03-02 2007-03-02 Improvement of protein production
EP07104226 2007-03-15
EP07116358 2007-09-13

Publications (1)

Publication Number Publication Date
AR086476A2 true AR086476A2 (es) 2013-12-18

Family

ID=39639553

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP080100873A AR065573A1 (es) 2007-03-02 2008-02-29 Metodo de produccion de proteinas heterologas por expresion de una proteina con dominio de trasnferencia de lipido relacionada con proteina reguladora de la esteroidogenesis aguda start.
ARP120101384A Pending AR086476A2 (es) 2007-03-02 2012-04-20 Metodos de produccion de una proteina de interes heterologa en una celula, para aumentar la productividad celular especifica de una proteina de interes de membrana o secretada en una celula, para aumentar la eficacia de transfeccion de una celula que expresa una proteina de interes de membrana o secretada en una celula y para identificar un modulador de la funcion de proteina con dominio start, vectores de expresion, celulas, proteinas, composiciones farmaceuticas y sus usos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP080100873A AR065573A1 (es) 2007-03-02 2008-02-29 Metodo de produccion de proteinas heterologas por expresion de una proteina con dominio de trasnferencia de lipido relacionada con proteina reguladora de la esteroidogenesis aguda start.

Country Status (24)

Country Link
US (4) US8221999B2 (es)
EP (3) EP2126093B1 (es)
JP (1) JP5467415B2 (es)
KR (1) KR20100015363A (es)
AR (2) AR065573A1 (es)
AU (1) AU2008223874B2 (es)
BR (1) BRPI0808542A2 (es)
CA (1) CA2677925A1 (es)
CY (1) CY1113710T1 (es)
DK (1) DK2126093T3 (es)
EA (1) EA018190B1 (es)
ES (1) ES2397274T3 (es)
HK (1) HK1136314A1 (es)
HR (1) HRP20121077T1 (es)
IL (1) IL200030A0 (es)
MX (1) MX2009009156A (es)
MY (1) MY148472A (es)
NZ (1) NZ580043A (es)
PL (1) PL2126093T3 (es)
PT (1) PT2126093E (es)
SG (1) SG182160A1 (es)
SI (1) SI2126093T1 (es)
TW (1) TWI419902B (es)
WO (1) WO2008107388A1 (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2126093B1 (en) 2007-03-02 2012-10-10 Boehringer Ingelheim Pharma GmbH & Co. KG Improvement of protein production
US8597909B2 (en) * 2008-09-10 2013-12-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of HSA-producing cells
WO2010128032A1 (en) * 2009-05-05 2010-11-11 Boehringer Ingelheim International Gmbh Cho / cert cell lines
JP2012526536A (ja) * 2009-05-15 2012-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング コンビナトリアルエンジニアリング
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN104531671A (zh) 2010-10-01 2015-04-22 现代治疗公司 设计核酸及其使用方法
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US8506797B2 (en) * 2011-04-10 2013-08-13 Therapeutic Proteins International, LLC Downstream bioprocessing device
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3682905B1 (en) 2011-10-03 2021-12-01 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
EP3378535B1 (en) 2011-10-28 2023-01-04 Prothena Biosciences Limited Humanized antibodies that recognize alpha-synuclein
US8852435B2 (en) * 2011-11-29 2014-10-07 Therapeutics Proteins International, LLC Purification and separation treatment assembly (PASTA) for biological products
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
CA2863953A1 (en) 2012-01-27 2013-08-01 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
KR101438533B1 (ko) * 2012-03-30 2014-09-17 한양대학교 산학협력단 적혈구계 세포의 인 비트로 확장방법
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243953A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of nuclear proteins
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US8886625B1 (en) 2012-10-31 2014-11-11 Google Inc. Methods and computer-readable media for providing recommended entities based on a user's social graph
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
US8972368B1 (en) * 2012-12-07 2015-03-03 Google Inc. Systems, methods, and computer-readable media for providing search results having contacts from a user's social graph
EP2970453B1 (en) 2013-03-13 2019-12-04 Prothena Biosciences Limited Tau immunotherapy
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
WO2015004633A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize islet-amyloid polypeptide (iapp)
WO2015004632A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize iapp
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
JP2017501848A (ja) 2013-11-19 2017-01-19 プロセナ バイオサイエンシーズ リミテッド 便秘症状からのレビー小体病の免疫療法のモニター
EP3116907A1 (en) 2014-03-12 2017-01-18 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
JP6728053B2 (ja) 2014-03-12 2020-07-22 プロセナ バイオサイエンシーズ リミテッド 抗ｍｃａｍ抗体及び関連する使用方法
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
JP2017512772A (ja) 2014-03-12 2017-05-25 プロセナ バイオサイエンシーズ リミテッド Ｌｇ１〜３に特異的な抗ラミニン４抗体
US10562973B2 (en) 2014-04-08 2020-02-18 Prothena Bioscience Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
TW202204596A (zh) 2014-06-06 2022-02-01 美商健臻公司 灌注培養方法及其用途
TWI776235B (zh) * 2014-06-09 2022-09-01 美商健臻公司 種子罐培養法(seed train processes)及其用途
TWI781507B (zh) 2015-01-28 2022-10-21 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI711631B (zh) 2015-01-28 2020-12-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI786505B (zh) 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
JP2018530540A (ja) 2015-09-16 2018-10-18 プロセナ バイオサイエンシーズ リミテッド 巨細胞動脈炎、リウマチ性多発筋痛症又は高安動脈炎の処置又は予防のための抗ｍｃａｍ抗体の使用
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
UA124148C2 (uk) 2016-05-02 2021-07-28 Протена Біосайенсіс Лімітед Антитіла, що розпізнають тау
KR20230070336A (ko) 2016-05-02 2023-05-22 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
WO2017191559A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Tau immunotherapy
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
EP3478715A2 (en) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
EP3478716A2 (en) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
EP3478714A2 (en) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
SG11201908079SA (en) 2017-03-29 2019-10-30 Boehringer Ingelheim Rcv Gmbh Recombinant host cell with altered membrane lipid composition
BR112019022906A2 (pt) 2017-05-02 2020-05-26 Prothena Biosciences Limited Anticorpos que reconhecem tau
AU2017434556A1 (en) 2017-09-28 2020-04-09 F. Hoffmann-La Roche Ag Dosing regimes for treatment of synucleinopathies
EP3698125A1 (en) * 2017-10-16 2020-08-26 Regeneron Pharmaceuticals, Inc. In situ raman spectroscopy systems and methods for controlling process variables in cell cultures
KR20210094610A (ko) 2018-11-26 2021-07-29 포티 세븐, 인코포레이티드 c-Kit에 대한 인간화 항체
SG11202108414UA (en) 2019-03-03 2021-08-30 Prothena Biosciences Ltd Antibodies recognizing tau
CN110592044B (zh) * 2019-07-26 2021-06-22 中国农业科学院蔬菜花卉研究所 蛋白激酶Fused编码基因及其在防治小菜蛾中的应用
CN111100865B (zh) * 2020-01-07 2022-03-18 江南大学 一种提高酿酒酵母丁醇耐受能力的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521297A (en) * 1993-06-04 1996-05-28 Salk Institute Biotechnology/Industrial Associates Nucleic acids encoding human metabotropic glutamate receptors
US5869250A (en) * 1996-12-02 1999-02-09 The University Of North Carolina At Chapel Hill Method for the identification of peptides that recognize specific DNA sequences
DE60025704T2 (de) * 1999-02-24 2006-09-07 Juan Saus Das goodpasture-antigen bindende protein
EP1514933A1 (en) * 1999-07-08 2005-03-16 Research Association for Biotechnology Secretory protein or membrane protein
US6972324B2 (en) * 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
JP2005515157A (ja) * 2001-05-25 2005-05-26 トマス ジェファソン ユニバーシティ 多様な治療様式のための主成分としての選択的スプライスフォーム
EP1560931B1 (en) * 2002-11-14 2011-07-27 Dharmacon, Inc. Functional and hyperfunctional sirna
US7326768B2 (en) * 2003-02-05 2008-02-05 Juan Saus Goodpasture antigen-binding protein isoforms and protein misfolded-mediated disorders
AU2004248165A1 (en) 2003-06-11 2004-12-23 Biogen Idec Ma Inc. Method to increase protein production in culture
US7244616B2 (en) * 2003-06-27 2007-07-17 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
JP2005035926A (ja) 2003-07-14 2005-02-10 Japan Science & Technology Agency セラミド輸送を促進する薬剤、該薬剤を製造する塩基配列、セラミド遊離を促進する活性の測定方法、及びセラミドの膜間移動を促進する活性の測定方法
AU2005248147A1 (en) * 2004-05-11 2005-12-08 Alphagen Co., Ltd. Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same
AU2006262603B2 (en) 2005-06-20 2011-01-06 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2126093B1 (en) 2007-03-02 2012-10-10 Boehringer Ingelheim Pharma GmbH & Co. KG Improvement of protein production
US20090018099A1 (en) * 2007-03-02 2009-01-15 Hitto Kaufmann Protein production
WO2010128032A1 (en) 2009-05-05 2010-11-11 Boehringer Ingelheim International Gmbh Cho / cert cell lines

Also Published As

Publication number Publication date
IL200030A0 (en) 2011-08-01
US20130177919A1 (en) 2013-07-11
PL2126093T3 (pl) 2013-03-29
AU2008223874A1 (en) 2008-09-12
HRP20121077T1 (hr) 2013-01-31
MX2009009156A (es) 2009-09-04
US8221999B2 (en) 2012-07-17
DK2126093T3 (da) 2013-01-07
ES2397274T3 (es) 2013-03-05
EA200901168A1 (ru) 2010-06-30
TW200846368A (en) 2008-12-01
WO2008107388A1 (en) 2008-09-12
EP2126093A1 (en) 2009-12-02
TWI419902B (zh) 2013-12-21
EP2522730A1 (en) 2012-11-14
AU2008223874B2 (en) 2014-06-26
JP5467415B2 (ja) 2014-04-09
NZ580043A (en) 2012-04-27
SI2126093T1 (sl) 2013-01-31
KR20100015363A (ko) 2010-02-12
JP2010519917A (ja) 2010-06-10
PT2126093E (pt) 2012-12-03
MY148472A (en) 2013-04-30
SG182160A1 (en) 2012-07-30
CY1113710T1 (el) 2016-06-22
US20130196430A1 (en) 2013-08-01
CA2677925A1 (en) 2008-09-12
US20080300207A1 (en) 2008-12-04
EA018190B1 (ru) 2013-06-28
BRPI0808542A2 (pt) 2014-08-26
EP2126093B1 (en) 2012-10-10
AR065573A1 (es) 2009-06-17
HK1136314A1 (en) 2010-06-25
EP2522729A1 (en) 2012-11-14
US20130197196A1 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
AR086476A2 (es) Metodos de produccion de una proteina de interes heterologa en una celula, para aumentar la productividad celular especifica de una proteina de interes de membrana o secretada en una celula, para aumentar la eficacia de transfeccion de una celula que expresa una proteina de interes de membrana o secretada en una celula y para identificar un modulador de la funcion de proteina con dominio start, vectores de expresion, celulas, proteinas, composiciones farmaceuticas y sus usos
Roubelakis et al. Amniotic fluid and amniotic membrane stem cells: marker discovery
PE20081655A1 (es) Medios racionalmente disenados para cultivo celular
AR066387A1 (es) Produccion de proteinas biologicamente activas
ES2484919T3 (es) Métodos que usan polipéptidos que tienen actividad de hidrolasa
PE20140867A1 (es) Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas y metodos para su uso
BR112016017736A2 (pt) métodos e produtos para produção e distribuição de ácido nucleico
BR122019022434B8 (pt) método para cultivar células de mamífero que secretam proteína heteróloga em um sobrenadante de cultura celular
BRPI0914440A8 (pt) Método para produção biogênica de etanol e cianobactéria geneticamente modificada
EA201991976A1 (ru) Метаболически оптимизированная клеточная культура
BR112019002238A2 (pt) polipeptídeo e célula manipulados, e, método de fermentação.
AR093626A1 (es) Proteinas de fusion de enzima lisosomal y usos de las mismas
AR076541A1 (es) Mutantes de fgf21 y usos del mismo
BR112015031233A2 (pt) métodos de produção de derivados de ácidos graxos omega-hidroxilados
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
AR051837A1 (es) Produccion de proteinas de fusion recombinante dentro de ensamblajes similares a cuerpos proteicos recombinantes (escpr)
BR112015021993A8 (pt) polipeptídeo, métodos para sua produção, métodos para cultivo de uma célula, composição farmacêutica, kit, e meio de cultura celular
ATE481483T1 (de) Verfahren zur herstellung eines rekombinanten polyklonalen proteins
AR070314A1 (es) Uso de peptidos de transito a plastidos derivados de glaucocystophytas
BR112021025359A2 (pt) Composições de proteína anti-vegf e métodos para a produção das mesmas
AR071232A1 (es) Proteina hibrida usada como vacuna contra toxinas shiga de e. coli
BR112016012229A2 (pt) métodos de produção de polipeptídeos
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
AR092630A1 (es) Metodos y composiciones para prevenir la incorporacion erronea de norleucina en proteinas
BRPI0410562A (pt) molécula recombinante e veìculo para expressão, liberação e purificação de polipeptìdeos alvo

Legal Events

Date Code Title Description
FB Suspension of granting procedure